Primary ovarian insufficiency is linked with lower family size in humans (women diagnosed 1995 to 2021) (median 1 less).
“Approximately 14% fewer women with POI will have children, but for those able to have children the median number is 1 less than for age-matched controls.”
Primary ovarian insufficiency is linked with higher Menopause Impact Scale in humans after age adjustment compared to other menopause etiologies.
“After age adjustment, symptom burden was highest in primary ovarian insufficiency, with the largest differences in vasomotor and genitourinary domains.”
Humansafter age adjustment compared to other menopause etiologiesfemales
Primary ovarian insufficiency impairs fertility in humans.
“Primary ovarian insufficiency (POI) is a disease that significantly affects the fertility, mental health, and physical health of up to 3.5% of women.”
Primary ovarian insufficiency is linked with lower telomere length in humans (non-iatrogenic hypergonadotropic hypogonadism).
“Females with POI due to estrogenic deficiency have slightly shorter mean telomere length (10,0 [7,9-10,7] kB, than healthy females of reproductive age (10,8 [10,0-13,1] кБ, р<0,001).”
Primary ovarian insufficiency is associated with telomere length in humans after adjusting for age (0.75 ± 0.09 vs 1.79 ± 0.12, P < 0.001; OR = 0.54, 95% CI = 0.43-0.68).
“patients with biochemical POI (n = 120) exhibited significantly shorter LTLs”
Humansafter adjusting for ageperipheral blood leukocytesfemales
Low polygenic risk score for age at natural menopause
↑upin humans1
1 study
Low polygenic risk score for age at natural menopause is associated with primary ovarian insufficiency in humans (women carrying rare variants; polygenic risk score below -0.5 standard deviation).
“low PGS (<-0.5 standard deviation) compounded POI risk in a subset of women carrying rare variants.”
FMR1 is associated with primary ovarian insufficiency in humans.
“Genetic studies have identified established and candidate abnormalities involving chromosomes, FMR1, folliculogenesis, meiosis, DNA repair, and mitochondrial function”
Gonadotropin-releasing hormone agonists lower the risk of primary ovarian insufficiency in humans during cyclophosphamide therapy (RR 0.16, 95% CI 0.07-0.37).
“Premature ovarian insufficiency occurred in 5 of 93 women receiving gonadotropin-releasing hormone agonists and in 28 of 69 controls, corresponding to a risk ratio of 0.16 (95% confidence interval (CI): 0.07-0.37).”
Endometriosis is linked with a higher risk of primary ovarian insufficiency in humans (versus propensity-score-matched comparison group without endometriosis) (3.7x risk).
“Patients with endometriosis had a 3.7x the risk of primary ovarian insufficiency and 12.4x the risk of surgical menopause (p < 0.0001)”
Humansversus propensity-score-matched comparison group without endometriosisfemales
Primary ovarian insufficiency raises the risk of Alzheimer's disease in humans.
“reproductive disorders such as primary ovarian insufficiency (POI) and polycystic ovary syndrome (PCOS) are associated with deficits in cognitive performance, altered DMN dynamics, and increased AD risk.”
Primary ovarian insufficiency is associated with systemic accelerated aging in humans.
“Primary ovarian insufficiency (POI) affects up to 3% of reproductive-aged women and is a critical yet underrecognized contributor to infertility and systemic accelerated aging.”
“In cases of primary ovarian insufficiency (POI), AMH levels are significantly reduced, aiding in diagnosis and distinguishing POI from other causes of amenorrhea.”
Among 899 women with primary ovarian insufficiency, 32.1% had Turner syndrome, a condition involving a missing or incomplete X chromosome.Among 899 women with primary ovarian insufficiency, 32.1% had Turner syndrome, a condition involving a missing or incomplete X chromosome.
A 22-question measure covering seven symptom areas was supported by three online studies of 2,915 US women aged 21–85.A 22-question measure covering seven symptom areas was supported by three online studies of 2,915 US women aged 21–85.